Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing

References

• Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. Br J Dermatol. 2015;172(6):1665–1668. doi:10.1111/BJD.13715
   PubMed Web of Science ®Google Scholar
• Vanaclocha F, Crespo-Erchiga V, Jiménez-Puya R, et al. Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study. Actas Dermosifiliogr. 2015;106(1):35–43. doi:10.1016/J.AD.2014.06.003
   PubMedGoogle Scholar
• Hilhorst N, Deprez E, Pauwels N, Grine L, Lambert J, Hoorens I. Patient-relevant outcomes in psoriasis: a systematic review. JAMA Dermatol. 2022;158(7):806. doi:10.1001/JAMADERMATOL.2022.1756
   PubMed Web of Science ®Google Scholar
• Katugampola RP, Lewis VJ, Finlay AY. The dermatology life quality index: assessing the efficacy of biological therapies for psoriasis. Br J Dermatol. 2007;156(5):945–950. doi:10.1111/J.1365-2133.2007.07817.X
   PubMed Web of Science ®Google Scholar
• Chan TC, Hawkes JE, Krueger JG. Interleukin 23 in the skin: role in psoriasis pathogenesis and selective interleukin 23 blockade as treatment. Ther Adv Chronic Dis. 2018;9(5):111–119. doi:10.1177/2040622318759282
   PubMed Web of Science ®Google Scholar
• Ataseven A, Temiz SA, Eren G, Özer İ, Dursun R. Comparison of anti-TNF and IL-inhibitors treatments in patients with psoriasis in terms of response to routine laboratory parameter dynamics. J Dermatolog Treat. 2022;33(2):1091–1096. doi:10.1080/09546634.2020.1801975
   PubMed Web of Science ®Google Scholar
• Gerdes S, Körber A, Biermann M, Karnthaler C, Reinhardt M. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life. J Dermatolog Treat. 2020;31(5):470–475. doi:10.1080/09546634.2020.1746734
   PubMed Web of Science ®Google Scholar
• Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12. doi:10.1016/0197-2456(95)00134-4
   PubMedGoogle Scholar
• Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg. 2011;9(8):672–677. doi:10.1016/j.ijsu.2011.09.004
   PubMed Web of Science ®Google Scholar
• López de Argumedo M, Reviriego E, Andrío E, et al. Revisión externa y validación de instrumentos metodológicos para la lectura crítica y la síntesis de la evidencia científica INFORMES, ESTUDIOS E INVESTIGACIÓN MINISTERIO DE SANIDAD Y CONSUMO.Servicio de Evaluación de Tecnologías Sani- tarias del País Vasco (Osteba) [External review and validation of methodological instruments for critical reading and synthesis of scientific evidence REPORTS, STUDIES AND RESEARCH MINISTRY OF HEALTH AND CONSUMPTION. Health Technology Assessment Service of the Basque Country (Osteba)]; Informes de Evaluación de Tecnologías Sanitarias: OSTEBA No 2006/02; 2006. Available from: http://www.euskadi.net/ejgvbiblioteka. Accessed June 25, 2022.
   Google Scholar
• Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Cochrane Database Syst Rev. 2020;1(1). doi:10.1002/14651858.CD011535.PUB3
   Google Scholar
• Lin PH, Tsai TF. Effects of risankizumab in patients with psoriasis previously treated with guselkumab: a case series. Eur J Dermatol. 2021;31(2):251–252. doi:10.1684/EJD.2021.4001
   PubMed Web of Science ®Google Scholar
• Al-Janabi A, Jabbar-Lopez ZK, Griffiths CEM, Yiu ZZN. Risankizumab vs. ustekinumab for plaque psoriasis: a critical appraisal. Br J Dermatol. 2019;180(6):1348–1351. doi:10.1111/BJD.17624
   PubMed Web of Science ®Google Scholar
• Warren RB, Blauvelt A, Poulin Y, et al. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a Phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Br J Dermatol. 2021;184(1):50–59. doi:10.1111/BJD.19341
   PubMed Web of Science ®Google Scholar
• van der Schoot LS, van den Reek JMPA, Grine L, et al. Dose reduction of the new generation biologics (IL-17 and IL-23 inhibitors) in psoriasis: study protocol for an international, pragmatic, multicenter, randomized, controlled, non-inferiority study-The BeNeBio study. Trials. 2021;22:1. doi:10.1186/S13063-021-05681-Z
   PubMed Web of Science ®Google Scholar
• Leonardi CL, See K, Burge R, et al. Number needed to treat network meta-analysis to compare biologic drugs for moderate-to-severe psoriasis. Adv Ther. 2022;39(5):2256–2269. doi:10.1007/S12325-022-02065-W
   PubMed Web of Science ®Google Scholar
• Singh S, Singh S, Thangaswamy A, Thangaraju P, Varthya SB. Efficacy and safety of Risankizumab in moderate to severe psoriasis: a systematic review and meta-analysis. Dermatol Ther. 2021;34:1. doi:10.1111/DTH.14487
   Web of Science ®Google Scholar
• Rentz AM, Skalicky AM, Esser D, et al. Reliability, validity, and the ability to detect change of the Psoriasis Symptom Scale (PSS) in patients with plaque psoriasis. J Dermatolog Treat. 2020;31(5):460–469. doi:10.1080/09546634.2019.1709612
   PubMed Web of Science ®Google Scholar
• Augustin M, Lambert J, Zema C, et al. Effect of Risankizumab on patient-reported outcomes in moderate to severe psoriasis: the UltIMMa-1 and UltIMMa-2 randomized clinical trials. JAMA Dermatol. 2020;156(12):1344–1353. doi:10.1001/JAMADERMATOL.2020.3617
   PubMed Web of Science ®Google Scholar
• Papp KA, Soliman AM, Done N, Carley C, Lemus Wirtz E, Puig L. Deterioration of health-related quality of life after withdrawal of Risankizumab treatment in patients with moderate-to-severe plaque psoriasis: a machine learning predictive model. Dermatol Ther (Heidelb). 2021;11(4):1291–1304. doi:10.1007/S13555-021-00550-8
   PubMed Web of Science ®Google Scholar
• Ruiz-Villaverde R, Ruiz-Carrascosa JC, Galán-Gutierrez M, Armario-Hita JC. Risankizumab: a pilot study of short-term effectiveness and safety in real clinical practice. Dermatol Ther. 2021;34(1). doi:10.1111/DTH.14711
   Web of Science ®Google Scholar
• Mastorino L, Castelli F, Stroppiana E, et al. Risankizumab shows faster response in bio naïve than in bio-experienced psoriatic patients. J Eur Acad Dermatol Venereol. 2022;36(10). doi:10.1111/JDV.18314
   Web of Science ®Google Scholar
• Lebwohl MG, Soliman AM, Yang H, et al. Impact of Risankizumab on PASI90 and DLQI0/1 duration in moderate-to-severe psoriasis: a post hoc analysis of four phase 3 clinical trials. Dermatol Ther. 2022;12(2):407–418. doi:10.1007/S13555-021-00660-3
   PubMed Web of Science ®Google Scholar
• Papp KA, Lebwohl MG, Puig L, et al. Long-term efficacy and safety of risankizumab for the treatment of moderate-to-severe plaque psoriasis: interim analysis of the LIMMitless open-label extension trial beyond 3 years of follow-up. Br J Dermatol. 2021;185(6):1135–1145. doi:10.1111/BJD.20595
   PubMed Web of Science ®Google Scholar
• Lebwohl M, Soliman AM, Yang H, Wang J, Freimark J, Puig L. Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis. J Dermatolog Treat. 2022;33(4):2094–2101. doi:10.1080/09546634.2021.1919287
   PubMed Web of Science ®Google Scholar
• Ohtsuki M, Fujita H, Watanabe M, et al. Efficacy and safety of risankizumab in Japanese patients with moderate to severe plaque psoriasis: results from the SustaIMM Phase 2/3 trial. J Dermatol. 2019;46(8):686–694. doi:10.1111/1346-8138.14941
   PubMed Web of Science ®Google Scholar
• Gkalpakiotis S, Cetkovska P, Arenberger P, et al. Risankizumab for the treatment of moderate-to-severe psoriasis: real-life multicenter experience from the Czech Republic. Dermatol Ther. 2021;11(4):1345–1355. doi:10.1007/S13555-021-00556-2
   PubMed Web of Science ®Google Scholar
• Thaçi D, Soliman AM, Eyerich K, et al. Patient-reported outcomes with risankizumab versus fumaric acid esters in systemic therapy-naïve patients with moderate to severe plaque psoriasis: a phase 3 clinical trial. J Eur Acad Dermatol Venereol. 2021;35(8):1686–1691. doi:10.1111/JDV.17109
   PubMed Web of Science ®Google Scholar
• Gooderham M, Pinter A, Ferris LK, et al. Long-term, durable, absolute psoriasis area and severity index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis. J Eur Acad Dermatol Venereol. 2022;36(6):855–865. doi:10.1111/JDV.18010
   PubMed Web of Science ®Google Scholar
• Sotiriou E, Bakirtzi K, Papadimitriou I, et al. A head-to-head comparison of risankizumab and ixekizumab for genital psoriasis: a real-life, 24-week, prospective study. J Eur Acad Dermatol Venereol. 2022;36(5):e359–e361. doi:10.1111/JDV.17880
   PubMed Web of Science ®Google Scholar
• Gordon KB, Strober B, Lebwohl M, et al. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Lancet. 2018;392(10148):650–661. doi:10.1016/S0140-6736(18)31713-6
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Leonardi CL, Gooderham M, et al. Efficacy and safety of continuous Risankizumab therapy vs treatment withdrawal in patients with moderate to severe plaque psoriasis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156(6):649–658. doi:10.1001/JAMADERMATOL.2020.0723
   PubMed Web of Science ®Google Scholar
• Reich K, Gooderham M, Thaçi D, et al. Risankizumab compared with Adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial. Lancet. 2019;394(10198):576–586. doi:10.1016/S0140-6736(19)30952-3
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Villanueva Quintero DG, Echeverría CM, Gu Y, Karunaratne M, Reyes Servín O. Body region involvement and quality of life in psoriasis: analysis of a randomized controlled trial of Adalimumab. Am J Clin Dermatol. 2016;17(6):691–699. doi:10.1007/S40257-016-0229-X
   PubMed Web of Science ®Google Scholar